Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
BONE THERAPEUTICS, the leading biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces today that it has received clearance from the Competent Authorities in Belgium and the UK for a phase I/IIa trial with its allogeneic cell therapy product ALLOB® for the treatment of delayed union fractures.
ALLOB® is an allogeneic, osteoblastic (i.e. bone-forming) cell therapy product. ALLOB® has already shown safety and efficacy in preclinical studies and has the potential to become a first-line treatment for impaired fracture healing, thanks to its minimally invasive percutaneous administration, avoiding the need for surgery.
This first-in-human, proof-of-concept, phase I/IIa study is a 6 months open-label trial to evaluate the safety and efficacy of ALLOB® in the treatment of delayed union fractures of long bones. Thirty-two patients will be enrolled in 10 centers. They will receive a single percutaneous administration of ALLOB® directly into the fracture site. ALLOB®-treated patients will be assessed in comparison to baseline at 2 weeks, 1, 3 and 6 months using clinical (e.g., pain, weight-bearing) and radiological evaluation.
Bone Therapeutics has already secured both 'Tissue Establishment' and 'GMP' Accreditation for the in-house manufacturing of ALLOB®. This not only allows Bone Therapeutics to have enhanced control over ALLOB®'s production, but secures the manufacturing runway for scale up of production to support ALLOB®'s further development.
Enrico Bastianelli, CEO of Bone Therapeutics commented, "This new clinical trial clearance from the Competent Authorities in Belgium and the UK is an important milestone in the development of ALLOB® and further validates Bone Therapeutics' clinical, regulatory and manufacturing capabilities. The only way to address delayed union fractures currently is invasive surgery which could have severe complications and a long hospital stay. With ALLOB®'s bone regenerative mode of action and minimally invasive administration, Bone Therapeutics' allogeneic product could become a first-line treatment."
ALLOB® is Bone Therapeutics' allogeneic bone cell therapy product. "Allogeneic" means that the cells are harvested from a healthy, universal donor, rather than from the patient (autologous). Currently in a Phase I/IIa clinical trial for delayed union fractures, ALLOB® also has the potential for systemic applications such as in osteogenesis imperfecta, a rare genetic bone disease characterized by bone fragility and fractures. ALLOB® has been classified as a tissue engineered product under the ATMP regulation 1394/2007EMA.
A delayed union fracture is defined as a bone that has not healed within the expected normal period of time after the initial injury (i.e., 3 to 4 months) and is at risk of non-healing. Around one million patients are affected by delayed union each year. Traditional options for the treatment of impaired fracture healing typically involve highly invasive surgery, which can be painful and require months of rehabilitation with no guarantee of success.
 Where cells are derived from a healthy, universal donor, rather than the patient.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Bones / Orthopedics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Therapeutics, Bone. "Bone Therapeutics' allogeneic osteoblastic product to enter clinic for the treatment of delayed union fractures." Medical News Today. MediLexicon, Intl., 3 Oct. 2013. Web.
13 Dec. 2013. <http://www.medicalnewstoday.com/releases/266897>
Therapeutics, B. (2013, October 3). "Bone Therapeutics' allogeneic osteoblastic product to enter clinic for the treatment of delayed union fractures." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266897.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.